Summary of Study ST000794

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000575. The data can be accessed directly via it's Project DOI: 10.21228/M8BM2Z This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)
Study IDST000794
Study TitleTargeted NEFA Panel of Myelin to Enhance Recovery of Function after SCI
Study SummaryTissue is from adult mouse spinal cord (SC). We are submitting these samples for Untargeted Profiling (unbiased metabolomics assay) and for lipid analysis. The lipid assays we request are 1) free fatty acid composition of lipids; 2) free fatty acid panel; 3) cholesterol concentration (free and bound); 4) Ceramides, including galactosyl and glucosyl; 5) sphingomyelin. The Untargeted profiling is our top priority, followed by the lipid assays as listed. All samples were snap frozen at the point of harvest and approximate weights are provided. The samples are submitted as intact pieces of tissue. There are 20 samples total, n=5 for each group that includes LF (low fat diet); HF (high fat diet); HFHS (high fat high sucrose diet); and Keto (ketogenic diet).
Institute
Mayo Clinic
Last NameScarisbrick
First NameIsobel
Address200 First St. SW, Rochester, Minnesota, 55905, USA
Emailscarisbrick.isobel@mayo.edu
Phone507-284-0124
Submit Date2017-07-12
Analysis Type DetailLC-MS
Release Date2021-01-19
Release Version1
Isobel Scarisbrick Isobel Scarisbrick
https://dx.doi.org/10.21228/M8BM2Z
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Collection:

Collection ID:CO000813
Collection Summary:Uninjured or SCI mice will be randomly assigned to one of four groups, LF (low fat diet); HF (high fat diet); HFHS (high fat high sucrose diet); and Keto (ketogenic diet). All diets will be obtained from Research Diets, NJ USA43,45. Dietary fat supplementation will be initiated at 1 week after SCI. This time point for intervention was chosen to provide a meaningful timeframe for clinical translation. Also, a 1 week period will allow time for mice to recover prior to providing access to wheel running (Aim 2). The impact of dietary fat supplementation on myelin metabolism will be examined after a period of 7 weeks, including determination of (i) the lipid profile of the myelin membrane using LC/MS/MS; and (ii) metabolic markers of spinal cord metabolism by NMR. Results will be correlated with (iii) cellular and molecular markers of spinal cord pathophysiology including the appearance of OPCs, oligodendroglia and myelin, axon health, astrogliosis and inflammation; and (iv) the extent of sensorimotor recovery. (v) In addition, to gauge the impact of the dietary fat on systemic metabolic status, Insulin and Glucose Resistance Tests will be performed at 7 weeks. Food intake (g/day) and body weight gain (% initial weight) will be measured daily until the endpoint of each experiment. Mice will be housed individually in a temperature-controlled facility with a 12:12-h light-dark cycle and ad libitum access to each diet and water. A Power Analysis was performed based on histological outcomes in mice with contusion compression injury. To detect a difference between groups of 20%, which would very meaningful, a group size of 8 will be needed to achieve a power of 0.85. An additional 2 mice per group has been added to account for mortality. The Mayo Clinic Institutional Animal Care and Use Committee has approved of the proposed studies.
Sample Type:Spinal cord
  logo